
Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Your AI-Trained Oncology Knowledge Connection!


Published: July 19th 2016 | Updated: